WELCOME TO THE MYOSITIS COMMUNITY: This Patient-To-Patient Community is for discussions relating to Myositis which is an inflammation of skeletal muscles, which are also called the voluntary muscles. These are the muscles you consciously control that help you move your body. An injury, infection or autoimmune disease can cause myositis.
For support and advice from others,
visit our Myositis Community
Myositis is the
chronic inflammation of muscle tissue. The
inflammatory myopathies are a group of diseases that involve myositis, accompanied
by muscle weakness. The primary types of chronic myositis are polymyositis, dermatomyositis, and inclusion
body myositis.
What
is Dermatomyositis?
Dermatomyositis is one of a group of
muscle diseases known as the inflammatory myopathies, which are characterized
by chronic muscle inflammation accompanied by muscle weakness.
Dermatomyositis' cardinal symptom is a skin rash that precedes, accompanies,
or follows progressive muscle weakness. The rash looks patchy, with
purple or red discolorations, and characteristically develops on the eyelids
and on muscles used to extend or straighten joints, including knuckles, elbows,
knees, and toes. Red rashes may also occur on the face, neck, shoulders,
upper chest, back, and other locations, and there may be swelling in the
affected areas. The rash sometimes occurs without obvious muscle
involvement. Adults with dermatomyositis may experience weight loss, a low-grade
fever, inflamed lungs, and be sensitive to light such that the rash or muscle
disease gets worse. Children and adults with dermatomyositis may develop
calcium deposits, which appear as hard bumps under the skin or in the muscle
(called calcinosis). Calcinosis most often occurs 1-3 years after the
disease begins. These deposits are seen more often in children with
dermatomyositis than in adults. In some cases of dermatomyositis, distal
muscles (muscles located away from the trunk of the body, such as those in the
forearms and around the ankles and wrists) may be affected as the disease
progresses. Dermatomyositis may be associated with collagen-vascular or
autoimmune diseases, such as lupus.
Is
there any treatment?
There is no cure for dermatomyositis,
but the symptoms can be treated. Options include medication, physical
therapy, exercise, heat therapy (including microwave and ultrasound), orthotics
and assistive devices, and rest. The standard treatment for
dermatomyositis is a corticosteroid drug, given either in pill form or
intravenously. Immunosuppressant drugs, such as azathioprine and
methotrexate, may reduce inflammation in people who do not respond well to
prednisone. Periodic treatment using intravenous immunoglobulin can also
improve recovery. Other immunosuppressive agents used to treat the
inflammation associated with dermatomyositis include cyclosporine A,
cyclophosphamide, and tacrolimus. Physical therapy is usually recommended
to prevent muscle atrophy and to regain muscle strength and range of
motion. Many individuals with dermatomyositis may need a topical
ointment, such as topical corticosteroids, for their skin disorder. They
should wear a high-protection sunscreen and protective clothing. Surgery
may be required to remove calcium deposits that cause nerve pain and recurrent
infections.
What
is the prognosis?
Most cases of dermatomyositis
respond to therapy. The disease is usually more severe and resistant to therapy
in individuals with cardiac or pulmonary problems.
What
research is being done?
The National Institute of
Neurological Disorders and Stroke (NINDS) and other institutes of the National
Institutes of Health (NIH) conduct research relating to dermatomyositis in
laboratories at the NIH and support additional research through grants to major
medical institutions across the country. Currently funded research is
exploring patterns of gene expression among the inflammatory myopathies, the
role of viral infection as a precursor to the disorders, and the safety and
efficacy of various treatment regimens.
Source: Information provided courtesy of the National Institute of Neurological Disorders and
Stroke (NINDS), a division of the National
Institutes of Health (NIH).
NINDS health-related material is
provided for information purposes only and does not necessarily represent
endorsement by or an official position of the National Institute of
Neurological Disorders and Stroke or any other Federal agency. Advice on the
treatment or care of an individual patient should be obtained through
consultation with a physician who has examined that patient or is familiar with
that patient's medical history.
o Myositis
o
Polymyositis
o
Inclusion Body Myositis